batirtze-areitio Batirtze Areitio Batirtze has over 5 years of experience in the biopharma and biotech industries. She joined ApexOnco in 2025 after working as an analyst at OncologyPipeline. She is a graduate of the University of Navarra, where she earned a degree in biochemistry. Novartis re-ups on PeptiDream’s macrocyclic peptide promise 30 April 2024 Lilly’s Verzenio, and CDK4/6 inhibition, hits a dead end in prostate cancer 30 April 2024 Ono goes for growth with $2.4bn Deciphera buy 29 April 2024 Astra accelerates as Acerand enters the PARP1 race 26 April 2024 Another sellside call for PD-(L)1 price competition 25 April 2024 A second attempt at heating up Anktiva 25 April 2024 Anktiva’s tortuous journey ends 23 April 2024 No Swiss surprise for Surface’s former owners 23 April 2024 Load More